DNLI logo

Denali Therapeutics Inc. Common Stock

DNLI

DNLI: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

more

Show DNLI Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of DNLI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by DNLI's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Engineered polypeptides Aug. 22, 2023
  • Patent Title: Phospho-rab antibodies, assays and methods of use thereof May. 30, 2023
  • Patent Title: Progranulin variants May. 09, 2023
  • Patent Title: Transferrin receptor transgenic models Mar. 28, 2023
  • Patent Title: Compounds, compositions, and methods Feb. 28, 2023
  • Patent Title: Anti-tau antibodies and methods of use thereof Jun. 28, 2022
  • Patent Title: Compounds, compositions and methods Apr. 19, 2022
  • Patent Title: Modulators of eukaryotic initiation factor 2b, compositions and methods Feb. 01, 2022
  • Patent Title: Compound, compositions, and methods Jan. 04, 2022
  • Patent Title: Kinase inhibitors and uses thereof Dec. 21, 2021
  • Patent Title: Compounds, compositions and methods Nov. 16, 2021
  • Patent Title: Anti-trem2 antibodies and methods of use thereof Sep. 21, 2021
  • Patent Title: Compounds, compositions, and methods Sep. 07, 2021
  • Patent Title: Compounds, compositions and methods Jul. 27, 2021
  • Patent Title: Substituted pyrimidines as lrkk2 inhibitors Jun. 08, 2021
  • Patent Title: Fusion proteins comprising enzyme replacement therapy enzymes Dec. 22, 2020
  • Patent Title: Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production Dec. 01, 2020
  • Patent Title: Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk1) Jul. 14, 2020
  • Patent Title: Compounds, compositions, and methods Mar. 17, 2020
  • Patent Title: Engineered polypeptides Oct. 29, 2019
  • Patent Title: Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production Aug. 06, 2019
  • Patent Title: Transferrin receptor transgenic models Dec. 04, 2018
  • Patent Title: Compounds, compositions and methods Nov. 20, 2018
  • Patent Title: Compounds, compositions, and methods Apr. 03, 2018
  • Patent Title: Compounds, compositions and methods Feb. 20, 2018
  • Patent Title: Compounds, compositions and methods Nov. 14, 2017
  • Patent Title: Oxadiazine compounds and methods of use thereof Oct. 31, 2017
  • Patent Title: Fused morpholinopyrimidines and methods of use thereof Sep. 26, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of DNLI in WallStreetBets Daily Discussion

DNLI News

Recent insights relating to DNLI

CNBC Recommendations

Recent picks made for DNLI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in DNLI

Corporate Flights

Flights by private jets registered to DNLI